The 2024 ESMO Gastrointestinal Cancers Congress (ESMO GI) is set to take place from June 26 to June 29 in Munich, Germany. Henlius will share the latest clinical data of phase 2 study (HLX22-GC-201) of its novel anti-HER2 monoclonal antibody (mAb), HLX22, combined with HANQUYOU (trastuzumab, HLX02, trade name: HERCESSI™️ in U.S. and Zercepac® in Europe) and chemotherapy for the first-line treatment of HER2-positive gastric/gastroesophageal junction (G/GEJ) cancer with Professor Jin Li of Shanghai East Hospital, School of Medicine, Tongji University as the leading principal investigator of this study. The results from HLX22-GC-201 were first released at the 2024 ASCO Gastrointestinal Cancers Symposium (ASCO GI) in January 2024, which showed that adding HLX22 to HLX02 (trastuzumab) and chemotherapy prolonged progression-free survival and enhanced antitumour response in patients with HER2-positive G/GEJ cancer in the first-line setting, with a manageable safety profile.

The data released at 2024 ESMO GI are as follows:
HLX22-GC-201
Title: HLX22 plus HLX02 and XELOX as first-line therapy for HER2-positive advanced gastric/gastroesophageal junction cancer: updated results from a randomized, double-blind phase 2 study
Abstract Number: 422P
Session: Poster Display Session
Leading PI: Jin Li, Shanghai East Hospital, School of Medicine, Tongji University

Onsite poster display time: 2024/6/27, 3:35 PM–4:30 PM GMT+2

As of now, no similar dual HER2 blockade therapy for the treatment of HER2-positive gastric cancer has received approval for commercialization globally. Until now, G/GEJ cancer still constitutes a major global health problem. Globally, there were around 1 million new cases in 2022. G/GEJ cancer generally carries a poor prognosis since it is often diagnosed at an advanced stage, with a 5-year relative survival rate of only 6%. The reported rates of HER2 positivity in patients with gastric cancer range from 12% to 23%, and the prognosis for patients with HER2-positive disease used to be even worse than those with HER2-negative disease. Currently, for patients with HER2-positive locally advanced/metastatic G/GEJ cancer, the standard first-line treatment is trastuzumab plus chemotherapy. Immunotherapies are recommended to be added for tumours with PD-L1 expression levels by combined positive score of greater than 1. However, the sustained efficacy and prognosis for these treatments need to be further improved.

HLX22 is an innovative anti-HER2 mAb that was introduced from AbClon, Inc. and further researched and developed by Henlius. HLX22 can bind to HER2 subdomain IV at a different binding site from trastuzumab, which allows the simultaneous binding of HLX22 and trastuzumab to HER2. Pre-clinical studies have showed that the combination therapy of HLX22 and trastuzumab inhibits the cell proliferation induced by epidermal growth factor (EGF) and Histidine-Rich Glycoprotein 1 (HRG1) and enhance the antitumour activity in vitro and in vivo. The phase 1 clinical trial of HLX22 demonstrates that HLX22 is well tolerated and has good safety profiles. Recently, the investigational new drug application (IND) for phase 3 international multicenter clinical study of HLX22 in combination with trastuzumab and chemotherapy for the first-line treatment of HER2-positive advanced gastric cancer has been approved by the United States Food and Drug Administration (FDA).

In the future, Henlius will keep focusing on patient needs and inspire more "made-by-Henlius" products with efficient and innovative in-house capabilities, aiming to provide highest quality solutions and services for patients worldwide.

https://mp.weixin.qq.com/s?__biz=MzI0Mzc1ODA3OA==&mid=2247510797&idx=1&sn=06308ca9bafa729750a2834edfe37af8&chksm=e96acd9cde1d448a04a46dc2b4d36338fb9b70bac1dbff6b2d62c7de8c3b4c1e1651eac6f6aa&mpshare=1&scene=1&srcid=0522UCVgbUk3hnB5ew2NqOj4&sharer_shareinfo=d0a03e2a181e4aeb6fd4d1bbfb4908e5&sharer_shareinfo_first=d0a03e2a181e4aeb6fd4d1bbfb4908e5#rd